Hematology

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

The gene therapy is currently under FDA review for the treatment of β-thalassemia across genotypes.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.

Results from the final analysis of the HOPE-B trial were presented at the 2022 EAHAD meeting.

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed results of the final analysis of the HOPE-B study.

Review top news and interview highlights from the week ending February 4, 2022.

Carl June, MD, discussed the longest-term follow-up data on CAR T-cell therapy so far.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH trial.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges in hemophilia A and B.

The approval was based on findings from the phase 2 KarMMa trial and the phase 1 Study CRB-401 trial.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.

Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Review top news and interview highlights from the week ending January 28, 2022.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.

The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.

Positive data from a phase 1 trial were presented at the 2021 ASCO meeting.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.

Review top news and interview highlights from the week ending January 21, 2022.

The FDA and Gamida Cell have reached a consensus on the comparability of omidubicel manufactured at different sites.

Data from the phase 2 QUILT-88 study were presented at the 2022 ASCO GI symposium.